// App-Quantinova.ai

: Fevipiprant antagonises prostaglandin D2-induced activation of type-2 CD8 T cells (Tc2)

Researchers

Presenter

  • Wentao Chen

Principal Investigators

  • Rowie Borst

  • Jian Luo

  • Mohammad M. Chizari

  • Luisa Chocarro De Erauso

  • Veit J. Erpenbeck

  • Shamsah Kazani

  • David A. Sandham

  • Luzheng Xue

Medical Centers

  • Respiratory Medicine Unit, University of Oxford, Oxford, United Kingdom,

  • Novartis AG, Basel, Switzerland

  • Novartis Institute for Biomedical Research, Cambridge, MA, United States

Locations

  • United Kingdom

  • Switzerland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Cluster of Differentiation 2AP

  • Cluster of differentiation 8A

  • Prostaglandin D2

Drug/Treatment

  • Prostaglandin

  • Fevipiprant

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved